VRNA · Insider Trading
Verona Pharma plc
Every open-market purchase and sale reported by VRNA officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-10-08 | Vikas Sinha | Director | MIXED | −94,112 | — |
| 2025-10-08 | James Aloysius Brady | Director | MIXED | −23,176 | — |
| 2025-10-08 | David Zaccardelli | President and CEO | MIXED | −12,176,144 | — |
| 2025-10-08 | Kathleen A. Rickard | Chief Medical Officer | MIXED | −2,432,868 | — |
| 2025-10-08 | Mark W Hahn | Chief Financial Officer | MIXED | −11,264,968 | — |
| 2025-10-08 | Christina Ackermann | Director | MIXED | −64,072 | — |
| 2025-10-08 | Martin Edwards | Director | MIXED | −157,992 | — |
| 2025-10-08 | Lisa Deschamps | Director | MIXED | −84,856 | — |
| 2025-10-08 | Kenneth Cunningham | Director | MIXED | −79,776 | — |
| 2025-10-08 | Anders Ullman | Director | MIXED | −358,856 | — |
| 2025-10-08 | Andrew Fisher | General Counsel | MIXED | −417,903 | — |
| 2025-10-08 | Michael Austwick | Director | MIXED | −12,712 | — |
| 2025-10-08 | David R Ebsworth | Director | MIXED | −1,498,099 | — |
| 2025-10-08 | Mahendra Shah | Director | MIXED | −93,472 | — |
| 2025-09-03 | Kathleen A. Rickard | Chief Medical Officer | G | −189,600 | — |
| 2025-09-03 | Mark W Hahn | Chief Financial Officer | G | −1,200,000 | — |
| 2025-09-03 | David Zaccardelli | President and CEO | G | −1,200,000 | — |
| 2025-08-05 | James Aloysius Brady | Director | MIXED | +23,176 | −$10.83K |
| 2025-08-05 | Andrew Fisher | General Counsel | MIXED | +11,304 | −$125.97K |
| 2025-08-05 | Mahendra Shah | Director | MIXED | +20,392 | −$47.42K |
| 2025-08-05 | Vikas Sinha | Director | MIXED | +19,672 | −$56.89K |
| 2025-08-05 | Kenneth Cunningham | Director | MIXED | +13,192 | −$142.06K |
| 2025-08-05 | Anders Ullman | Director | M | +24,000 | — |
| 2025-08-05 | Kathleen A. Rickard | Chief Medical Officer | MIXED | +12,552 | −$766.75K |
| 2025-08-05 | David Zaccardelli | President and CEO | MIXED | +46,784 | −$2.75M |
| 2025-08-05 | David R Ebsworth | Director | MIXED | +22,096 | −$25.03K |
| 2025-08-05 | Martin Edwards | Director | MIXED | +13,192 | −$142.06K |
| 2025-08-05 | Mark W Hahn | Chief Financial Officer | MIXED | +46,784 | −$2.75M |
| 2025-08-05 | Michael Austwick | Director | MIXED | +12,712 | −$148.37K |
| 2025-08-05 | Christina Ackermann | Director | MIXED | +22,192 | −$23.76K |
| 2025-08-05 | Lisa Deschamps | Director | MIXED | +14,536 | −$124.39K |
| 2025-07-09 | Kathleen A. Rickard | Chief Medical Officer | MIXED | +48,448 | −$430.38K |
| 2025-07-09 | David Zaccardelli | President and CEO | MIXED | +139,192 | −$1.03M |
| 2025-07-09 | Andrew Fisher | General Counsel | MIXED | +46,600 | −$451.52K |
| 2025-07-09 | Mark W Hahn | Chief Financial Officer | MIXED | +139,192 | −$1.03M |
| 2025-06-18 | Andrew Fisher | General Counsel | M | +80,000 | +$160.90K |
| 2025-06-18 | Andrew Fisher | General Counsel | MIXED | — | −$761.10K |
| 2025-06-13 | Mark W Hahn | Chief Financial Officer | Sell | −400,000 | −$4.56M |
| 2025-06-13 | David Zaccardelli | President and CEO | Sell | −400,000 | −$4.56M |
| 2025-05-29 | Mark W Hahn | Chief Financial Officer | Sell | −400,000 | −$3.73M |
| 2025-05-29 | David Zaccardelli | President and CEO | Sell | −400,000 | −$3.73M |
| 2025-05-22 | Vikas Sinha | Director | MIXED | — | −$1.42M |
| 2025-05-22 | Vikas Sinha | Director | MIXED | — | −$1.20M |
| 2025-05-16 | Andrew Fisher | General Counsel | MIXED | — | −$516.56K |
| 2025-05-16 | Christina Ackermann | Director | MIXED | — | −$260.25K |
| 2025-05-08 | Kathleen A. Rickard | Chief Medical Officer | Sell | −114,984 | −$1.01M |
| 2025-05-05 | David Zaccardelli | President and CEO | MIXED | −387,008 | −$5.31M |
| 2025-05-05 | Kathleen A. Rickard | Chief Medical Officer | MIXED | +800 | −$440.35K |
| 2025-05-05 | David R Ebsworth | Director | M | +140,000 | +$270.73K |
| 2025-05-05 | Mark W Hahn | Chief Financial Officer | MIXED | −387,008 | −$5.31M |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Mark W Hahn | Chief Financial Officer | 3,285,280 | $351.23M |
| David Zaccardelli | President and CEO | 3,285,280 | $351.23M |
| Andrew Fisher | General Counsel | 931,984 | $99.64M |
| Martin Edwards | Director | 72,000 | $7.70M |
| Kenneth Cunningham | Director | 72,000 | $7.70M |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the VRNA quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.